Ebony Cotton
Researcher
Also affiliated: University of Tennessee Health Science Center (2020)
Unknown Researcher
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Ebony Cotton's research has focused on the intersection of pharmacology, toxicology, and molecular biology. Her work has investigated the molecular mechanisms underlying the effects of various compounds, including the antineoplastic agent vorinostat. Cotton has examined gene expression regulation in neoplastic cells, with attention to receptors such as the progesterone receptor and estrogen receptor alpha, as well as oncogenes like Erb-b2. Her research has utilized human tumor cell lines to study these cellular processes. Cotton has published five papers, accumulating 23 citations, and holds an h-index of 1. She has collaborated with researchers Yifan Zhang, Leihong Wu, and Joshua Xu, all from the National Center for Toxicological Research, on shared publications.
Metrics
- h-index: 1
- Publications: 5
- Citations: 24
Selected Publications
-
Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1 (2024)
-
Abstract B125: Molecular profiling basal 2 subtypes of triple-negative breast cancer cells and their response to histone deacetylase inhibitor (2020)
-
Modulation of Estrogen α and Progesterone Receptors in Triple Negative Breast Cancer Cell Lines: The Effects of Vorinostat and Indole-3-Carbinol In Vitro (2020)
-
Abstract 5196: Vorinostat exhibits anticancer effects through modulation of nuclear receptors and tumor suppressor genes in sub-types of triple negative breast cancer cells (2019)
Collaboration Network
Top Collaborators
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
- Enhancing pharmacogenomic data accessibility and drug safety with large language models: a case study with Llama3.1
Similar Researchers
Based on overlapping research topics